The Opharmic Team are extremely pleased to let you know that amongst over 650 submissions, we are selected to be on the prestigious list of Forbes Asia 100 to Watch in 2022!
The recognition from Forbes Asia can't come at a better time as we look forward to bringing you some big news here at Opharmic throughout the rest of 2022 and beyond.
Throughout the pandemic since 2020, Opharmic has:
The 100 to Watch list spotlights small companies and startups on the rise across the APAC region addressing real-world challenges with fresh thinking and innovative products and services. The selection is based on metrics such as a positive impact on the region or industry, a track record of strong revenue growth or ability to attract funding, promising business models or markets, and a persuasive story.
The announcement will be featured in the September issue of Forbes Asia.
We would like to take this opportunity to express our sincere gratitude to our investors and partners for the continued support!
Opharmic announce grant of Japanese patent covering novel MeticTouch ocular drug induction technology
The Managements of Opharmic are pleased to announce that the Japan Patent Office has granted the patent covering the MeticTouch ocular induction platform technology. Extensively covering the method, design, and applications of the novel drug delivery system, the MeticTouch platform offers exclusive opportunities to its partners by providing non-invasive delivery solutions to therapeutics at all stages of drug discovery.
The granted patent enables our continued efforts in establishing research and commercial partnerships with new and existing pharma companies in Japan. Demonstrating JPO’s recognition of Opharmic’s innovation, the granting of this patent lays a powerful springboard to the launch of our MeticTouch partnership programme.
Click here to learn more about partnering with Opharmic.
The Opharmic team are so thrilled to announce that amongst the top 20 companies shortlisted from over 500 applicants, and 4 highly competitive finalists, Opharmic has been voted as the Grand Prize winner of the APAC Medtech Innovator Competition 2021, taking home a US$175,000 cash award in addition the valuable winner title endorsed by the global MedTech industry! We are also extremely proud to be the very first Hong Kong company who has won this representative competition throughout the MTI history.
In addition, we are tremendously happy to also bagged the Cambridge Consultants Product Development Prize of US$25,000, and more importantly for the endorsements on our product development and regulatory strategy from one of the globally leading medical device development firm.
Stay tuned for upcoming press release and featuring events!
During these difficult times, people in different areas around the world, are all contributing to combat the pandemic. We at Opharmic are doing everything we can to support fighting the virus.
While our operations and R&D activities are well on track thanks to technology, to ensure the safety and well-being of our team, we’re adopting a WFH + flexible office schedule in order for our staffs to minimise public contacts. In light of the recent stabilisation of low new case numbers in Hong Kong, our tentative date of return back to normal office hours is 4 May 2020. Should there be any changes in situation, this shall be revised accordingly.
To contribute in the recovery of our society post-pandemic, we are currently developing various measures and programmes including special vacancies for 2020 graduates. Should you have any questions regarding Opharmic, or ideas in how our company/ ultrasound technology may contribute to combating the pandemic, we welcome you to contact us for further discussion at firstname.lastname@example.org.
Image Source: H. GOV. [Online]. Available: https://www.coronavirus.gov.hk/eng/index.html.
We’re proud to announce that effective from 29 Jan 2020 (after CNY), we will relocate to our brand-new 2000+ sq. ft office at Hong Kong Science Park to accommodate our growth. The new and larger office demonstrates our ever-expanding focus on technology research and development, in addition to supporting our needs in hardware product development.
Our office number will remain the same as +852 3703 5840. While mails sent to our old address remains temporarily available for a short period via redirection, we would appreciate if all our contacts can update our address to the following accordingly:
Unit 209, 2/F, Lakeside One
No.8 Science Park West Avenue
Hong Kong Science Park
Shatin, N.T., Hong Kong
Should you have any questions on the relocation, please feel free to contact us. We look forward to bringing more revolutionary medical innovation to patients and clinicians worldwide at our greatly improved office surroundings.
Four years ago, we were young graduates filling in our Incu-Bio application in a corner of a university computer barn, with a vision to bring our ultrasound ocular drug delivery innovation from bench to bedside.
From Sonikure to Opharmic, on 28 Dec 2019, the company officially graduated from the Hong Kong Science Park Incu-Bio Programme after an extremely rewarding journey. Below is a summary on what we’ve achieved:
Special thanks to Hong Kong Science & Technology Park and all their amazing teams for everything they’ve done. From hours after hours of investors introduction meetings, to that cold beer together after a day of fruitful event overseas.
Stay tuned for our graduation ceremony in 2020! It’s a brand-new page for us here at Opharmic, and we can only see unlimited opportunities and exciting challenges ahead of us.
Today we are thrilled to announce a new milestone toward our core value of being a holistic eye care platform!
Sonikure has rebranded as Opharmic.
We have moved our website to opharmic.com, where you can find out more about us. All our telephone lines remain unchanged. As for emails, all our Sonikure email remains temporarily active until further notice.